Balazs Gyorffy

List of Publications by Year in Descending Order

247 papers	13,742 citations	55 h-index	112 g-index
283 ext. papers	17,874 ext. citations	6.4 avg, IF	7.34 L-index

#	Paper	IF	Citations
247	Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features.. *Biomedicines*, **2022**, 10,	4.8	3
246	The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients.. *Journal of Cellular Biochemistry*, **2022**,	4.7	3
245	Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
244	DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer.. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2022**, 188722	11.2	1
243	RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53.. *Cellular and Molecular Life Sciences*, **2022**, 79, 270	10.3	0
242	Transcriptomic Mapping of Non-Small Cell Lung Cancer p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.. *Frontiers in Immunology*, **2021**, 12, 786069	8.4	1
241	Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. *Frontiers in Oncology*, **2021**, 11, 714550	5.3	1
240	Oncogene-mediated metabolic gene signature predicts breast cancer outcome. *Npj Breast Cancer*, **2021**, 7, 141	7.8	2
239	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-**B**. *Oncogene*, **2021**, 40, 1077-1090	9.2	9
238	Pancancer survival analysis of cancer hallmark genes. *Scientific Reports*, **2021**, 11, 6047	4.9	243
237	TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	99
236	Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 1937-1955	4.9	2
235	Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. *Frontiers in Immunology*, **2021**, 12, 642860	8.4	6
234	A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors. *PLoS ONE*, **2021**, 16, e0249558	3.7	3
233	HGK promotes metastatic dissemination in prostate cancer. *Scientific Reports*, **2021**, 11, 12287	4.9	3
232	The prognostic significance of FOXC2 gene expression in cancer: A comprehensive analysis of RNA-seq data from the cancer genome atlas. *Cancer Genetics*, **2021**, 254-255, 58-64	2.3	1
231	MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction. *PLoS ONE*, **2021**, 16, e0245824	3.7	13

230	RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence. *IScience*, **2021**, 24, 102618	6.1	2
229	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. *Cancers*, **2021**, 13,	6.6	3
228	Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2021**, 34, 102366	6	2
227	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. *Science Translational Medicine*, **2021**, 13,	17.5	3
226	BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 268-277	6.2	10
225	Different mutations in SARS-CoV-2 associate with severe and mild outcome. *International Journal of Antimicrobial Agents*, **2021**, 57, 106272	14.3	59
224	muTarget: A platform linking gene expression changes and mutation status in solid tumors. *International Journal of Cancer*, **2021**, 148, 502-511	7.5	21
223	Prognostic significance of hedgehog signaling network-related gene expression in breast cancer patients. *Journal of Cellular Biochemistry*, **2021**, 122, 577-597	4.7	4
222	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. *Cellular Oncology (Dordrecht)*, **2021**, 44, 569-580	7.2	5
221	Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. *Computational and Structural Biotechnology Journal*, **2021**, 19, 4101-4109	6.8	97
220	Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. *Computational and Structural Biotechnology Journal*, **2021**, 19, 949-960	6.8	27
219	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. *Cancers*, **2021**, 13,	6.6	5
218	Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. *Carcinogenesis*, **2021**, 42, 804-813	4.6	3
217	Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. *Journal of Medical Internet Research*, **2021**, 23, e27633	7.6	88
216	Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. *Frontiers in Oncology*, **2021**, 11, 647269	5.3	0
215	Survival analysis in breast cancer using proteomic data from four independent datasets. *Scientific Reports*, **2021**, 11, 16787	4.9	7
214	Genomic Mapping of Splicing-Related Genes Identify Amplifications in , and in Luminal Breast Cancer. *Cancers*, **2021**, 13,	6.6	1
213	COVIDOUTCOME-estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome. *Database: the Journal of Biological Databases and Curation*, **2021**, 2021,	5	5

212	TGF-β potentiates Vδ2 T cell adoptive immunotherapy of cancer.. *Cell Reports Medicine*, **2021**, 2, 100473	18	4
211	Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. *Diagnostics*, **2020**, 10,	3.8	3
210	Research funding: past performance is a stronger predictor of future scientific output than reviewer scores. *Journal of Informetrics*, **2020**, 14, 101050	3.1	13
209	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. *Frontiers in Oncology*, **2020**, 10, 712	5.3	3
208	Is there a golden age in publication activity? An analysis of age-related scholarly performance across all scientific disciplines. *Scientometrics*, **2020**, 124, 1081-1097	3	6
207	Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. *Cellular Oncology (Dordrecht)*, **2020**, 43, 431-444	7.2	5
206	RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. *Theranostics*, **2020**, 10, 7974-7992	12.1	18
205	Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. *Molecular Cancer Research*, **2020**, 18, 414-423	6.6	6
204	Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. *Cancer and Metastasis Reviews*, **2020**, 39, 211-233	9.6	19
203	Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. *Gynecologic Oncology*, **2020**, 156, 654-661	4.9	18
202	miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas. *Cancers*, **2020**, 13,	6.6	3
201	SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells. *Scientific Reports*, **2020**, 10, 2262	4.9	20
200	FOXM1 functions collaboratively with PLAU to promote gastric cancer progression. *Journal of Cancer*, **2020**, 11, 788-794	4.5	16
199	The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 585-604	4.4	3
198	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 476, 855-862	5.1	2
197	A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. *International Journal of Cancer*, **2020**, 147, 3250-3261	7.5	4
196	Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting. *Scientific Reports*, **2020**, 10, 14403	4.9	5
195	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. *Cancers*, **2020**, 12,	6.6	11

194	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. *JAMA Network Open*, **2020**, 3, e209486	10.4	2
193	Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	16
192	GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. *Cancers*, **2020**, 12,	6.6	2
191	The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness. *Cancer Genomics and Proteomics*, **2019**, 16, 491-503	3.3	7
190	Evidence for the Oocyte Mosaicism Selection model on the origin of Patau syndrome (trisomy 13). *Acta Obstetricia Et Gynecologica Scandinavica*, **2019**, 98, 1558-1564	3.8	1
189	Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39. *Scientific Reports*, **2019**, 9, 343	4.9	2
188	Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. *Annals of Clinical and Translational Neurology*, **2019**, 6, 990-1005	5.3	7
187	Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	8
186	BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK. *Molecular Cancer Research*, **2019**, 17, 1627-1638	6.6	20
185	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERαbreast cancer. *Nature Communications*, **2019**, 10, 2115	17.4	27
184	ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. *International Journal of Cancer*, **2019**, 145, 3140-3151	7.5	64
183	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. *PLoS ONE*, **2019**, 14, e0209134	3.7	8
182	Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. *Journal of Hematology and Oncology*, **2019**, 12, 29	22.4	19
181	Mapping Bromodomains in breast cancer and association with clinical outcome. *Scientific Reports*, **2019**, 9, 5734	4.9	5
180	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. *Frontiers in Oncology*, **2019**, 9, 1486	5.3	15
179	Identifying Cancers Impacted by CDK8/19. *Cells*, **2019**, 8,	7.9	17
178	JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. *International Journal of Cancer*, **2019**, 145, 3376-3388	7.5	34
177	Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival. *Journal of Advanced Research*, **2019**, 20, 105-116	13	18

176	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. *OncoImmunology*, **2019**, 8, e1629780	7.2	12
175	Prognostic value of DLGAP5 in colorectal cancer. *International Journal of Colorectal Disease*, **2019**, 34, 1455-1465	3	17
174	Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. *Cancers*, **2019**, 11,	6.6	8
173	Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 10921	4.9	2
172	Low level of exosomal long non-coding RNA is a prognostic biomarker in colorectal cancer. *RNA Biology*, **2019**, 16, 1339-1345	4.8	40
171	The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. *BMC Cancer*, **2019**, 19, 1046	4.8	7
170	Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. *Cancers*, **2019**, 11,	6.6	15
169	Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology. *Cancers*, **2019**, 11,	6.6	9
168	FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. *ELife*, **2019**, 8,	8.9	41
167	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. *Frontiers in Immunology*, **2019**, 10, 2802	8.4	13
166	Differential impact of classical and non-canonical NF-**B** pathway-related gene expression on the survival of breast cancer patients. *Journal of Cancer*, **2019**, 10, 5191-5211	4.5	11
165	Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment. *Cell Biology and Toxicology*, **2019**, 35, 1-14	7.4	13
164	A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years. *Briefings in Bioinformatics*, **2019**, 20, 1004-1010	13.4	6
163	Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer. *Frontiers in Pharmacology*, **2018**, 9, 1522	5.6	18
162	Evaluating mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer. *Frontiers in Pharmacology*, **2018**, 9, 1581	5.6	7
161	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 3433-3446	12.9	28
160	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. *British Journal of Cancer*, **2018**, 118, 1107-1114	8.7	17
159	Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. *Molecular and Cellular Endocrinology*, **2018**, 471, 105-117	4.4	12

158	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. *Nature Medicine*, **2018**, 24, 1469-1480	50.5	64
157	Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Scientific Reports*, **2018**, 8, 9227	4.9	787
156	Afatinib restrains K-RAS-driven lung tumorigenesis. *Science Translational Medicine*, **2018**, 10,	17.5	70
155	Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. *Journal of Clinical Investigation*, **2018**, 128, 5307-5321	15.9	12
154	Alterations in SCAI Expression during Cell Plasticity, Fibrosis and Cancer. *Pathology and Oncology Research*, **2018**, 24, 641-651	2.6	5
153	linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer. *Transcription*, **2018**, 9, 17-29	4.8	20
152	Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. *Royal Society Open Science*, **2018**, 5, 181006	3.3	197
151	Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. *JCO Precision Oncology*, **2018**, 2,	3.6	2
150	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. *Breast Cancer Research*, **2018**, 20, 145	8.3	11
149	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. *PLoS ONE*, **2018**, 13, e0207776	3.7	4
148	Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030. *Clinical Epidemiology*, **2018**, 10, 1093-1108	5.9	16
147	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. *OncoImmunology*, **2018**, 7, e1526613	7.2	40
146	Transcriptome evolution from breast epithelial cells to basal-like tumors. *Oncotarget*, **2018**, 9, 453-463	3.3	9
145	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. *Breast Cancer Research and Treatment*, **2018**, 172, 725-732	4.4	7
144	Factors influencing the scientific performance of Momentum grant holders: an evaluation of the first 117 research groups. *Scientometrics*, **2018**, 117, 409-426	3	8
143	Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. *Cancer Letters*, **2018**, 437, 89-99	9.9	16
142	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. *Nature Communications*, **2018**, 9, 1983	17.4	31
141	HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation. *EMBO Molecular Medicine*, **2017**, 9, 181-197	12	46

140	Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes. *Scientific Reports*, **2017**, 7, 40070	4.9	23
139	The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. *Journal of Pathology*, **2017**, 242, 73-89	9.4	28
138	ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1. *Gut*, **2017**, 66, 666-682	19.2	21
137	Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?. *Human Pathology*, **2017**, 65, 31-40	3.7	14
136	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. *Cancer Research*, **2017**, 77, 3317-3324	10.1	80
135	Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years. *International Journal of Gynecology and Obstetrics*, **2017**, 138, 261-266	4	2
134	Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. *EMBO Journal*, **2017**, 36, 3336-3355	13	69
133	Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E9608-E9617	11.5	45
132	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. *Oncotarget*, **2017**, 8, 12558-12575	3.3	70
131	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. *Clinical Cancer Research*, **2017**, 23, 6650-6660	12.9	104
130	Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation. *Scientific Reports*, **2017**, 7, 7358	4.9	6
129	ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. *Autophagy*, **2017**, 13, 1386-1403	10.2	86
128	KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. *International Journal of Cancer*, **2017**, 140, 930-937	7.5	18
127	Cancer heterogeneity determined by functional proteomics. *Seminars in Cell and Developmental Biology*, **2017**, 64, 132-142	7.5	10
126	Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. *Oncogene*, **2017**, 36, 5709-5721	9.2	61
125	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	15
124	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. *PLoS ONE*, **2017**, 12, e0175128	3.7	20
123	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. *Oncotarget*, **2017**, 8, 26122-26128	3.3	14

122	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. *Oncotarget*, **2017**, 8, 21733-21740	3.3	13
121	PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. *Oncotarget*, **2017**, 8, 69520-69526	3.3	8
120	DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. *Oncotarget*, **2017**, 8, 77207-77218	3.3	20
119	Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment. *Current Pharmaceutical Design*, **2017**, 23, 5-28	3.3	1
118	Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis. *Cell Metabolism*, **2016**, 24, 447-461	24.6	108
117	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. *Npj Breast Cancer*, **2016**, 2, 16033	7.8	29
116	miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. *Breast Cancer Research and Treatment*, **2016**, 160, 439-446	4.4	507
115	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1866, 300-319	11.2	60
114	Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. *Scientific Reports*, **2016**, 6, 37169	4.9	20
113	Transcription Factor ZBP-89 Drives a Feedforward Loop of ß-Catenin Expression in Colorectal Cancer. *Cancer Research*, **2016**, 76, 6877-6887	10.1	15
112	HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. *Cancer Research*, **2016**, 76, 4443-56	10.1	41
111	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5929-5938	12.9	47
110	Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. *Clinical Cancer Research*, **2016**, 22, 2271-82	12.9	39
109	BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters. *Pathobiology*, **2016**, 83, 1-12	3.6	5
108	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. *Cancer Research*, **2016**, 76, 927-39	10.1	103
107	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. *PLoS Medicine*, **2016**, 13, e1002193	11.6	48
106	TP53 mutation hits energy metabolism and increases glycolysis in breast cancer. *Oncotarget*, **2016**, 7, 67183-67195	3.3	34
105	LDB1 overexpression is a negative prognostic factor in colorectal cancer. *Oncotarget*, **2016**, 7, 84258-84270	3.3	7

104	Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity. *Oncotarget*, **2016**, 7, 1262-75	3.3	58
103	HIF-3α promotes colorectal tumor cell growth by activation of JAK-STAT3 signaling. *Oncotarget*, **2016**, 7, 11567-79	3.3	17
102	Potential options for managing LOX+ ER- breast cancer patients. *Oncotarget*, **2016**, 7, 32893-901	3.3	8
101	Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. *Oncotarget*, **2016**, 7, 49322-49333	3.3	643
100	Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins. *Cancer Research*, **2016**, 76, 4068-80	10.1	50
99	Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e366	10.7	8
98	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. *Oncologist*, **2016**, 21, 1063-78	5.7	35
97	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. *International Journal of Cancer*, **2016**, 138, 87-97	7.5	79
96	Multigene prognostic tests in breast cancer: past, present, future. *Breast Cancer Research*, **2015**, 17, 11	8.3	173
95	Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. *EMBO Journal*, **2015**, 34, 1493-508	13	24
94	HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. *Cancer Discovery*, **2015**, 5, 944-59	24.4	56
93	Synaptic mitochondria: a brain mitochondria cluster with a specific proteome. *Journal of Proteomics*, **2015**, 120, 142-57	3.9	40
92	Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14313-8	11.5	30
91	A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. *Genome Medicine*, **2015**, 7, 104	14.4	49
90	Classical pathology and mutational load of breast cancer - integration of two worlds. *Journal of Pathology: Clinical Research*, **2015**, 1, 225-38	5.3	57
89	Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. *Science Signaling*, **2015**, 8, ra98	8.8	114
88	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. *Cell Reports*, **2015**, 13, 108-121	10.6	64
87	Signal Transduction Pathways of TNAP: Molecular Network Analyses. *Sub-Cellular Biochemistry*, **2015**, 76, 185-205	5.5	2

86	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. *Nature Communications*, **2015**, 6, 10044	17.4	81
85	Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. *Molecular Oncology*, **2015**, 9, 58-67	7.9	25
84	Glutamate enrichment as new diagnostic opportunity in breast cancer. *International Journal of Cancer*, **2015**, 136, 1619-28	7.5	76
83	Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer. *International Journal of Cancer*, **2015**, 136, 2091-8	7.5	8
82	Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database. *Journal of Thoracic Oncology*, **2015**, 10, 1020-6	8.9	29
81	A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. *Current Cancer Drug Targets*, **2015**, 15, 665-83	2.8	31
80	A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results. *PLoS ONE*, **2015**, 10, e0129267	3.7	9
79	Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts. *Aging*, **2015**, 7, 816-38	5.6	25
78	Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. *Oncotarget*, **2015**, 6, 13334-46	3.3	17
77	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. *Nature Communications*, **2015**, 6, 6285	17.4	95
76	BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer. *EBioMedicine*, **2015**, 2, 1932-43	8.8	41
75	The pioneer factor PBX1 is a novel driver of metastatic progression in ER-positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
74	Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. *Current Cancer Drug Targets*, **2015**, 15, 739-49	2.8	50
73	Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. *Breast Cancer Research and Treatment*, **2014**, 144, 561-8	4.4	3
72	Brain protein expression changes in WAG/Rij rats, a genetic rat model of absence epilepsy after peripheral lipopolysaccharide treatment. *Brain, Behavior, and Immunity*, **2014**, 35, 86-95	16.6	18
71	A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers. *Molecular Oncology*, **2014**, 8, 1441-57	7.9	24
70	Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis. *PLoS ONE*, **2014**, 9, e112541	3.7	58
69	MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. *BMC Cancer*, **2014**, 14, 837	4.8	41

68	Predicting the chance of relapse after tamoxifen treatment in breast cancer. *Biomarkers in Medicine*, **2014**, 8, 77-9	2.3	1
67	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. *Molecular Oncology*, **2014**, 8, 508-19	7.9	49
66	Biomarkers for systemic therapy in ovarian cancer. *Current Cancer Drug Targets*, **2014**, 14, 259-73	2.8	6
65	Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer.. *Journal of Clinical Oncology*, **2014**, 32, 5557-5557	2.2	
64	Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 1065-1065	2.2	
63	A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 140, 219-32	4.4	140
62	Combined Wnt/ß-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. *Cell Reports*, **2013**, 5, 1214-27	10.6	57
61	Predicting effective drug combinations via network propagation **2013**,		1
60	New network topology approaches reveal differential correlation patterns in breast cancer. *BMC Systems Biology*, **2013**, 7, 78	3.5	29
59	Lower risk for Down syndrome associated with longer oral contraceptive use: a case-control study of women of advanced maternal age presenting for prenatal diagnosis. *Contraception*, **2013**, 87, 455-8	2.5	7
58	Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. *Journal of Histochemistry and Cytochemistry*, **2013**, 61, 330-9	3.4	24
57	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1490-9	11.5	120
56	Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis. *Microarrays (Basel, Switzerland)*, **2013**, 2, 228-42		20
55	Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. *PLoS ONE*, **2013**, 8, e59503	3.7	16
54	Current composite-feature classification methods do not outperform simple single-genes classifiers in breast cancer prognosis. *Frontiers in Genetics*, **2013**, 4, 289	4.5	30
53	The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. *PLoS ONE*, **2013**, 8, e56707	3.7	23
52	Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS ONE*, **2013**, 8, e82241	3.7	1161
51	Meta-analysis of 59 gene expression based biomarker candidates predicting survival after tamoxifen treatment in breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, e11564-e11564	2.2	

50	Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 13799-804	11.5	108
49	Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. *BMC Genomics*, **2012**, 13, 334	4.5	102
48	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. *PLoS ONE*, **2012**, 7, e51862	3.7	749
47	Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. *International Journal of Cancer*, **2012**, 131, 95-105	7.5	33
46	ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. *Pathology and Oncology Research*, **2012**, 18, 331-42	2.6	36
45	RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. *Breast Cancer Research and Treatment*, **2012**, 132, 1025-34	4.4	76
44	Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. *Journal of Histochemistry and Cytochemistry*, **2012**, 60, 491-501	3.4	15
43	Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. *Endocrine-Related Cancer*, **2012**, 19, 197-208	5.7	550
42	A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. *Current Cancer Drug Targets*, **2012**, 12, 857-72	2.8	42
41	Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. *PLoS ONE*, **2012**, 7, e30804	3.7	40
40	Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?. *Translational Andrology and Urology*, **2012**, 1, 192-3	2.3	
39	Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. *Cancer Science*, **2011**, 102, 2248-54	6.9	42
38	Jetset: selecting the optimal microarray probe set to represent a gene. *BMC Bioinformatics*, **2011**, 12, 474	3.6	189
37	Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. *Anticancer Research*, **2011**, 31, 711-8	2.3	31
36	Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. *Histopathology*, **2010**, 56, 727-39	7.3	30
35	PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. *British Journal of Cancer*, **2010**, 102, 361-8	8.7	30
34	Biomarkers downstream of RAS: a search for robust transcriptional targets. *Current Cancer Drug Targets*, **2010**, 10, 858-68	2.8	21
33	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. *Genome Medicine*, **2010**, 2, 53	14.4	36

32	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Research and Treatment*, **2010**, 123, 725-31	4.4	1940
31	Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?. *Clinical and Experimental Metastasis*, **2010**, 27, 371-87	4.7	62
30	Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. *Journal of Pathology*, **2010**, 222, 310-9	9.4	107
29	Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. *PLoS ONE*, **2009**, 4, e5645	3.7	67
28	Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. *Breast Cancer Research and Treatment*, **2009**, 118, 433-41	4.4	68
27	A prognostic gene expression index in ovarian cancer - validation across different independent data sets. *Journal of Pathology*, **2009**, 218, 273-80	9.4	80
26	Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. *Disease Markers*, **2008**, 25, 1-16	3.2	76
25	Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. *International Journal of Cancer*, **2008**, 123, 2013-9	7.5	63
24	Helicobacter pylori and antrum erosion-specific gene expression patterns: the discriminative role of CXCL13 and VCAM1 transcripts. *Helicobacter*, **2008**, 13, 112-26	4.9	37
23	A Web-based data warehouse on gene expression in human malignant melanoma. *Journal of Investigative Dermatology*, **2007**, 127, 394-9	4.3	36
22	Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells. *Advances in Enzyme Regulation*, **2007**, 47, 41-62		
21	Highly expressed genes are associated with inverse antisense transcription in mouse. *Journal of Genetics*, **2007**, 86, 103-9	1.2	7
20	Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. *Oncology Research and Treatment*, **2007**, 30, 421-6	2.8	7
19	Resistance-associated signatures in breast cancer. *Recent Results in Cancer Research*, **2007**, 176, 37-50	1.5	
18	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. *International Journal of Cancer*, **2006**, 118, 1699-712	7.5	120
17	Use of routinely collected amniotic fluid for whole-genome expression analysis of polygenic disorders. *Clinical Chemistry*, **2006**, 52, 2013-20	5.5	12
16	Computational analysis reveals 43% antisense transcription in 1182 transcripts in mouse muscle. *DNA Sequence*, **2006**, 17, 422-30		3
15	Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects. *American Heart Journal*, **2006**, 151, 878-81	4.9	28

List of Publications

14	Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. *Melanoma Research*, **2006**, 16, 147-55	3.3	11
13	Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. *British Journal of Cancer*, **2006**, 95, 339-46	8.7	42
12	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. *Oncogene*, **2006**, 25, 1743-52	9.2	95
11	Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers. *Folia Histochemica Et Cytobiologica*, **2006**, 44, 111-6	1.4	30
10	Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. *Oncogene*, **2005**, 24, 7542-51	9.2	62
9	Application of Microarrays for the Prediction of Therapy Response in Breast Cancer. *Cancer Genomics and Proteomics*, **2005**, 2, 255-263	3.3	
8	Examination of Hardy-Weinberg equilibrium in papers of Kidney International: an underused tool. *Kidney International*, **2004**, 65, 1956-8	9.9	24
7	Missed calculations and new conclusions: re-calculation of genotype distribution data published in Journal of Investigative Dermatology, 1998-2003. *Journal of Investigative Dermatology*, **2004**, 122, 644-6	4.3	13
6	Re-calculated Hardy-Weinberg values in papers published in Atherosclerosis between 1995 and 2003. *Atherosclerosis*, **2004**, 173, 141-3	3.1	13
5	Gender-specific association of vitamin D receptor polymorphism combinations with type 1 diabetes mellitus. *European Journal of Endocrinology*, **2002**, 147, 803-8	6.5	60
4	Survival analysis in breast cancer using proteomic data from four independent datasets		1
3	Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments		1
2	TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues		6
1	SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ER breast cancer		1